Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

Inclusion Criteria:

• Ability to understand and sign a written informed consent form

• Receiving antiretroviral therapy with a ritonavir-boosted PI and two NRTIscontinuously for ≥ 6 months preceding the screening visit

• Plasma HIV-1 RNA concentrations (at least two measurements) at undetectable levels for ≥ 6 months prior to the screening visit and HIV-1 RNA < 50 copies/mL at the screeningvisit

• On their first or second antiretroviral drug regimen; if on their second regimen,HIV-1 RNA ≤ 50 copies/mL required at the time of the first change in antiretroviraldrugs, and no HIV RNA > 50 copies/mL measured at two consecutive time points afterfirst achieving HIV RNA < 50 copies/mL

• No previous use of any approved or experimental nonnucleoside reverse transcriptaseinhibitor (NNRTI) drug for any length of time

• Have a genotype prior to starting initial antiretroviral therapy and no knownresistance to any of the study agents

• Normal ECG

• Hepatic transaminases (AST and ALT) ≤ 5 x upper limit of normal (ULN)

• Total bilirubin ≤ 1.5 mg/dL, or normal direct bilirubin

• Adequate hematologic function (absolute neutrophil count ≥ 1,000/mm^3; platelets ≥ 50,000/mm^3; hemoglobin ≥ 8.5 g/dL)

• Serum amylase ≤ 5 x ULN (subjects with serum amylase > 5 x ULN eligible if serumlipase ≤ 5 x ULN)

• Adequate renal function (estimated glomerular filtration rate ≥ 70 mL/min according tothe Cockcroft-Gault formula)

• Males and females of childbearing potential must agree to utilize highly effectivecontraception methods (two separate forms of contraception, one of which must havebeen an effective barrier method, or been nonheterosexually active, practice sexualabstinence, or have a vasectomized partner) from screening throughout the duration ofthe study period and for 30 days following the last dose of study drug.

• Age ≥ 18 years

• Life expectancy ≥ 1 year

Exclusion Criteria:

• A new AIDS-defining condition diagnosed within 30 days prior to screening exceptcluster of differentiation 4 (CD4) cell count and/or percentage criteria

• Females who are breastfeeding

• Positive serum pregnancy test (female of childbearing potential)

• Proven or suspected acute hepatitis 30 days prior to study entry.

• Current alcohol or substance abuse judged by the Investigator to potentially interferewith subject compliance.

• History of malignancy within 5 years prior to study entry or ongoing malignancy otherthan cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, noninvasivecutaneous squamous carcinoma

• Active, serious infections requiring parenteral antibiotic or antifungal therapywithin 30 days prior to baseline

• Anticipated need to initiate contraindicated drugs during the study, including drugsnot to be used with FTC, TDF, RPV; or subjects with known allergies to the excipientsof FTC/RPV/TDF STR tablets or Truvada® tablets

• All investigational drugs

• Medications and use of herbal/natural supplements excluded or to be used with cautionwhile participating in the study, including those not to be taken with Viread®,Emtriva®, Truvada, and Rilpivirine.

• Participation in any other clinical trial without prior approval from the sponsor wasprohibited while participating in this trial

• Treatment with immunosuppressant therapies or chemotherapeutic agents within 3 monthsof study screening, or expected to receive these agents or systemic steroids duringthe study

• History of liver disease, including Gilbert's Disease

• Any other clinical condition or prior therapy making the subject unsuitable for thestudy or unable to comply with the dosing requirements